Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real‐world treatment outcomes
Sign Up to like & getrecommendations! Published in 2021 at "Investigational New Drugs"
DOI: 10.1007/s10637-021-01115-4
Abstract: Purpose Despite the established activity of regorafenib in metastatic colorectal cancer (CRC), gastrointestinal stromal tumor (GIST), and hepatocellular carcinoma (HCC), its toxicity profile has limited clinical use. We aimed to evaluate the pharmacokinetics of regorafenib… read more here.
Keywords: real world; treatment; regorafenib; oral multikinase ... See more keywords
Molecular predictors of response to first-line systemic therapies in advanced hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.3_suppl.534
Abstract: 534 Background: With numerous advances in systemic therapy for advanced hepatocellular carcinoma (HCC) over the past several years, there are now multiple first-line treatment options which can be considered. These options include combination atezolizumab with… read more here.
Keywords: oral multikinase; atezo bev; first line; monotherapy ... See more keywords
First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
Sign Up to like & getrecommendations! Published in 2022 at "PLOS ONE"
DOI: 10.1371/journal.pone.0279786
Abstract: Abstract: Background Oral multikinase inhibitors and immune checkpoint inhibitors (ICIs) are effective in advanced hepatocellular carcinoma (aHCC) but may increase cost. This study compared the cost-effectiveness of oral multikinase inhibitors and ICIs in first-line patients… read more here.
Keywords: multikinase inhibitors; cost; line; treatment ... See more keywords